Jade Biosciences, Inc. Capital Expenditures
Jade Biosciences, Inc. (JBIO) reported Capital Expenditures of $196.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-10
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $3.00K.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $57.00K.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $64.00K, a 1500.00% increase year-over-year.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $32.00K, a 3.03% decline year-over-year.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $196.00K.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $142.00K, a 27.18% decline from fiscal 2022.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $195.00K, a 7.73% increase from fiscal 2021.
- Jade Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $181.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $60.00K derived: sum of 2 quarters · filed 2026-03-06 | $196.00K 10-K · filed 2026-03-06 | |
| 2025-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $193.00K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $136.00K 10-Q · filed 2026-08-10 | |||
| 2023-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $96.00K derived: sum of 2 quarters · filed 2025-03-27 | $126.00K derived: sum of 3 quarters · filed 2025-03-27 | $142.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $62.00K derived: sum of 2 quarters · filed 2024-11-12 | $78.00K 10-Q · filed 2024-11-12 | $82.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $46.00K 10-Q · filed 2024-08-12 | $50.00K derived: sum of 3 quarters · filed 2024-08-12 | $83.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $16.00K 10-Q · filed 2024-05-13 | $20.00K derived: sum of 2 quarters · filed 2024-05-13 | $53.00K derived: sum of 3 quarters · filed 2024-05-13 | $183.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $37.00K derived: sum of 2 quarters · filed 2024-03-25 | $167.00K derived: sum of 3 quarters · filed 2024-03-25 | $195.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $163.00K derived: sum of 2 quarters · filed 2023-11-13 | $191.00K 10-Q · filed 2023-11-13 | $276.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $158.00K 10-Q · filed 2023-08-14 | $243.00K derived: sum of 3 quarters · filed 2023-08-14 | $299.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $28.00K 10-Q · filed 2023-05-15 | $113.00K derived: sum of 2 quarters · filed 2023-05-15 | $169.00K derived: sum of 3 quarters · filed 2023-05-15 | $169.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $141.00K derived: sum of 2 quarters · filed 2023-03-29 | $141.00K derived: sum of 3 quarters · filed 2023-03-29 | $181.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $56.00K derived: sum of 2 quarters · filed 2022-11-14 | $96.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $40.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $40.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |